Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04590781
Title Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Xencor, Inc.

Merkel cell carcinoma

lung small cell carcinoma


Pembrolizumab + XmAb18087


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.